Correlation of Parathyroid Hormone Levels with Mineral Status in End-stage Renal Disease Patients.

Parathyroid hormone (PTH) is the main regulator of calcium, phosphate, magnesium, sodium, and potassium homeostasis. Therefore, this study was conducted to evaluate the relationship between PTH and aforementioned minerals in end-stage renal disease (ESRD) patients.

Aim: The aim of this study was to estimate serum intact parathormone (iPTH) and other biochemical parameters in ESRD patients and to find correlation between serum iPTH and biochemical parameters in the study group.

Results: This cross-sectional study included 60 clinically diagnosed patients of ESRD of age (>18 years), either sex. Disordered mineral metabolism is common complications of ESRD patients. The mean value of calcium, phosphorus, and magnesium was 7.90 ± 1.16 mg/dL, 6.44 ± 1.72 mg/dL, and 2.57 ± 0.62 mg/dL, respectively, indicating hypocalcemia, hyperphosphatemia, and hypermagnesemia in ESRD patients. To compensate the deranged mineral status, increased levels of PTH were seen in ESRD patients with mean value of 173.93 ± 62.62 pg/mL. There was a statistically significant positive correlation found between PTH and S. creatinine ( P ≤ 0.001; r = 0.596), whereas the statistically significant negative correlation found between PTH and eGFR ( P ≤ 0.001; r = -0.525). A significant positive correlation found between PTH and phosphorous ( P = 0.003; r = 0.378) and potassium ( P ≤ 0.001; r = 0.421). On the other hand, significant negative correlation found with calcium ( P ≤ 0.001; r = -0.805) and corrected calcium ( P = <0.001; r = -0.769). But nonsignificant association was found with magnesium, sodium, and calcium × phosphorous ( P > 0.05).

Conclusion: It was concluded that PTH is playing crucial role in mineral metabolism; it should be frequently assessed in order to prevent any untoward mineral decompensation and to prevent complications like bone disease and extra skeletal calcification, and decrease cardiac disease risk in ESRD patients.